SCHEMBL6734212

SCHEMBL6734212

COCCOc1ccc(-c2cc(-c3cccc([N+](=O)[O-])c3)nc(-c3cccc([N+](=O)[O-])c3)c2)cc1OCCOC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ TOP1 P11387 1/20 0.43
▸ PDE4D Q08499 2/20 0.42
▸ PDE4B Q07343 2/20 0.42
▸ ABCG2 Q9UNQ0 1/20 0.41
▸ KMO O15229 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733409 0.80 KIT (0.42) MAPTALDH1A1RAB9ANPC1RECQL
SCHEMBL2002273 0.76 MAPT (0.55) MAPTALDH1A1TDP1RAB9ANPC1
SCHEMBL6998883 0.73 ALDH1A1 (0.63) MAPTALDH1A1THRBTDP1RAB9A
SCHEMBL7736167 0.73 TOP1 (0.39) MAPTL3MBTL1RAB9ANPC1TOP1
SCHEMBL17525543 0.73 ALDH1A1 (0.59) MAPTALDH1A1TDP1RAB9ANPC1
SCHEMBL6732151 0.72 MEN1 (0.51) MAPTALDH1A1THRBTDP1RAB9A
SCHEMBL6431028 0.71 MAPT (0.59) MAPTALDH1A1TDP1RAB9ANPC1
SCHEMBL8619827 0.71 APP (0.50) MAPTALDH1A1THRBTDP1RAB9A
SCHEMBL874001 0.71 POLB (0.52) MAPTALDH1A1L3MBTL1ABCG2SMN1; SMN2
Acetonitrile SCHEMBL28046866 0.71 MAPT (0.49) MAPTALDH1A1TDP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 — — US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 — — EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK MAPT 2310/4885ALDH1A1 757/4885THRB 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback